Dr. Sarayut L. Geater, MD - Prince of Songkla University - Dr.

Dr. Sarayut L. Geater

MD

Prince of Songkla University

Dr.

Hat Yai, Songkhla | Thailand

Main Specialties: Internal Medicine, Pulmonary Disease

Additional Specialties: Pulmonologist

ORCID logohttps://orcid.org/0000-0002-3494-8268


Top Author

Dr. Sarayut L. Geater, MD - Prince of Songkla University - Dr.

Dr. Sarayut L. Geater

MD

Introduction

Dr. Sarayut L. Geater is a board-certified pulmonologist, and has been working as a lecturer in the Faculty of Medicine, Prince of Songkla University, since 2006. His main field of interest is lung cancer. He has been involved in various types of research, e.g. epidemiology, basic medical science and clinical trials.
Due to the many unique features of lung cancer and its treatment in this region of the world, including social economics, health policy and access to care which differ from those of western countries, a better understanding of lung cancer in this setting is particularly important. This is the motivation driving Dr. Geater’s research.
Dr Geater agrees with the world’s most famous guideline stated by NCCN that “the best management of any patient with cancer is in a clinical trial” and that “participation in clinical trials is [to be] especially encouraged”.

Primary Affiliation: Prince of Songkla University - Hat Yai, Songkhla , Thailand

Specialties:

Additional Specialties:

Research Interests:


View Dr. Sarayut L. Geater’s Resume / CV

Education

Jun 2005
Mahidol University
Pulmonologist
Jun 2003
Prince of Songkla University
Internal Medicine
Jun 1999
Chiang Mai University
M.D.

Experience

Oct 2009
LUX Lung 3
PI

Publications

20Publications

566Reads

1411Profile Views

1305PubMed Central Citations

Procedure-related tumour seeding in lung cancer with malignant pleural effusion: Radiological features and outcomes.

J Med Imaging Radiat Oncol 2018 Oct 6;62(5):619-624. Epub 2018 Apr 6.

Division of Diagnostic Imaging, Department of Radiology, Songklanagarind Hospital, Prince of Songkla University, Songkhla, Thailand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1754-9485.12727DOI Listing
October 2018
20 Reads
0.951 Impact Factor

Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).

Lung Cancer 2016 12 20;102:30-37. Epub 2016 Oct 20.

Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.10.007DOI Listing
December 2016
26 Reads
6 Citations
3.960 Impact Factor

P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC.

J Thorac Oncol 2016 Oct 22;11(10S):S210-S211. Epub 2016 Sep 22.

Department Of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen/GERMANY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.08.067DOI Listing
October 2016
29 Reads
5.282 Impact Factor

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma.

J Thorac Oncol 2016 10 21;11(10):1736-44. Epub 2016 Jul 21.

Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.05.038DOI Listing
October 2016
33 Reads
6 Citations
5.282 Impact Factor

Single nucleotide polymorphisms in the Gc gene for vitamin D binding protein in common cancers in Thailand.

Asian Pac J Cancer Prev 2015 ;16(8):3339-44

Central Research Laboratory, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand E-mail :

View Article

Download full-text PDF

Source
February 2016
17 Reads
4 Citations
1.500 Impact Factor

Cerebral venous thrombosis: comparing characteristics of infective and non-infective aetiologies: a 12-year retrospective study.

Postgrad Med J 2015 Dec 23;91(1082):670-4. Epub 2015 Oct 23.

Faculty of Medicine, Department of Internal Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/postgradmedj-2015-133592DOI Listing
December 2015
14 Reads
1 Citation
1.550 Impact Factor

Predictors of hospital outcome in patients with cerebral venous thrombosis.

J Stroke Cerebrovasc Dis 2014 Nov-Dec;23(10):2725-9. Epub 2014 Oct 11.

Department of Surgical Nursing, Faculty of Nursing Science, Prince of Songkla University, Hat Yai, Songkhla, Thailand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2014.06.020DOI Listing
November 2015
25 Reads
3 Citations
1.993 Impact Factor

Differences in cancer incidence among predominantly Muslim and Buddhist subpopulations in Songkhla.

Asian Pac J Cancer Prev 2014 ;15(22):9979-83

Epidemiology Unit, Faculty of Medicine, Prince of Songkla University, Thailand E-mail :

View Article

Download full-text PDF

Source
August 2015
17 Reads
5 Citations
1.500 Impact Factor

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.

Lancet Oncol 2015 Jul 4;16(7):830-8. Epub 2015 Jun 4.

Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(15)00026-1DOI Listing
July 2015
35 Reads
81 Citations
24.690 Impact Factor

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer.

J Thorac Oncol 2015 Jun;10(6):883-9

*Division of Respiratory and Respiratory Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand; †Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, China; ‡Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China; §Department of Pulmonary Medicine, Xiangya Hospital, Central South University, Changsha, China; ‖Department of Internal Medicine, Jiangsu Provincial Tumor Hospital, Nanjing, Jiangsu, China; ¶Shanghai Lung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China; #Yunnan Tumor Hospital (The Third Affiliated Hospital of Kunming Medical University), Kunming, Yunnan Province, China; **Cancer Center, First Hospital of Jilin University, Changchun, China; ††Department of Oncology Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China; ‡‡Oncology Department, Lin Yi Tumor Hospital, Linyi, Shandong Province, China; §§Department of Internal Medicine, Konkuk University Medical Center, Seoul, South Korea; ‖‖Medical Statistics Department, Keele University, Keele, United Kingdom; ¶¶Boehringer Ingelheim International Trading, Shanghai, China; and ##Boehringer Ingelheim GmbH, Ingelheim, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000517DOI Listing
June 2015
24 Reads
10 Citations
5.282 Impact Factor

Prognostic significance of 14-3-3γ overexpression in advanced non-small cell lung cancer.

Asian Pac J Cancer Prev 2014 ;15(8):3513-8

Department of Biomedical Sciences, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand E-mail :

View Article

Download full-text PDF

Source
January 2015
16 Reads
9 Citations
1.500 Impact Factor

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Lancet Oncol 2014 Feb 15;15(2):213-22. Epub 2014 Jan 15.

Division of Respiratory and Respiratory Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70604-1DOI Listing
February 2014
31 Reads
346 Citations
24.690 Impact Factor

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

J Clin Oncol 2013 Sep 1;31(27):3327-34. Epub 2013 Jul 1.

Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.44.2806DOI Listing
September 2013
73 Reads
551 Citations
18.430 Impact Factor

Validation of the OSTA index for discriminating between high and low probability of femoral neck and lumbar spine osteoporosis among Thai postmenopausal women.

J Med Assoc Thai 2004 Nov;87(11):1286-92

Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University.

View Article

Download full-text PDF

Source
November 2004
15 Reads
7 Citations

Top co-authors

Yi-Long Wu
Yi-Long Wu

Guangdong Lung Cancer Institute

8
Nobuyuki Yamamoto
Nobuyuki Yamamoto

Wakayama Medical University

6
Martin Schuler
Martin Schuler

West German Cancer Center

6
Lecia V Sequist
Lecia V Sequist

Massachusetts General Hospital Cancer Center

6
Tony Mok
Tony Mok

The Chinese University of Hong Kong

5
Vera Hirsh
Vera Hirsh

McGill University

5
Chun-Ming Tsai
Chun-Ming Tsai

Taipei Veterans General Hospital

5
James Chih-Hsin Yang
James Chih-Hsin Yang

National Taiwan University Hospital

5